GlassScriptPhysician profile
Christopher Chauvin
NPI 1104489459
$2,932.47
in general payments reported to CMS, 2019-2025
31 companies · $1,812 in 2025
The $1,812 reported for 2025 was more than what 92% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $99.71 · 2023: $585 · 2024: $436 · 2025: $1,812.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,833.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,832.76 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $503.71 | 2023-2025 | Ozempic, Wegovy, Rybelsus |
| Bayer Healthcare Pharmaceuticals INC. | $386.84 | 2022-2025 | |
| Supernus Pharmaceuticals, INC. | $198.26 | 2025 | Qelbree |
| Novartis Pharmaceuticals Corporation | $192.71 | 2022-2025 | |
| Astrazeneca Pharmaceuticals LP | $182.82 | 2022-2025 | Airsupra, Farxiga, Breztri |
| Boehringer Ingelheim Pharmaceuticals, INC. | $145.06 | 2023-2025 | Ofev, Jascayd |
| Lilly USA, LLC | $138.70 | 2022-2025 | Mounjaro, Zepbound |
| Sumitomo Pharma America, INC. | $125.90 | 2024-2025 | Gemtesa |
| Exact Sciences Corporation | $110.35 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Glaxosmithkline, LLC. | $108.26 | 2023-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Abbvie INC. | $102.95 | 2023-2025 | Qulipta, Vraylar |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $82.52 | 2023-2025 | Xifaxan, Relistor, Trulance |
| Janssen Pharmaceuticals, INC | $74.78 | 2022-2023 | Xarelto, Spravato |
| Insulet Corporation | $59.64 | 2025 | Omnipod |
| Amgen INC. | $58.03 | 2023-2024 | Repatha |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $48.41 | 2024-2025 | Cuvitru, Glassia |
| Phathom Pharmaceuticals, INC. | $46.29 | 2025 | Voquezna |
| Pfizer INC. | $42.73 | 2024-2025 | |
| Actelion Pharmaceuticals US, INC. | $42.23 | 2025 | Opsynvi, Uptravi |
| Otsuka America Pharmaceutical, INC. | $37.57 | 2025 | Rexulti |
| Ibsa Pharma INC. | $35.38 | 2022-2024 | Tirosint, Licart |
| Seqirus USA INC | $32.47 | 2023 | Flucelvax Quadrivalent, Fluad Quadrivalent |
| Jazz Pharmaceuticals INC. | $27.02 | 2025 | |
| Xeris Pharmaceuticals, INC. | $24.08 | 2025 | Gvoke Hypopen |
| Merck Sharp & Dohme LLC | $22.96 | 2025 | Zerbaxa |
| Verona Pharma, INC. | $22.32 | 2025 | Ohtuvayre |
| Axsome Therapeutics, INC. | $18.22 | 2025 | Sunosi |
| Dexcom, INC. | $17.22 | 2025 | Dexcom G6 Transmitter |
| Esperion Therapeutics, INC. | $16.54 | 2025 | Nexletol |
| Corcept Therapeutics | $15.69 | 2023 | Korlym |
| Astellas Pharma US INC | $12.81 | 2023 | Myrbetriq |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Chauvin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.